Notable Labs is redefining cancer treatment by taking a functional approach to precision oncology in blood cancers.
This cutting-edge science will facilitate drug development and enable pharmaceutical companies to get new therapies to patients faster.
Notable has developed a custom precision medicine platform that blends high-throughput flow cytometry with advanced automation and a streamlined analysis pipeline. This platform has been optimized to analyze drug sensitivity across many drug classes in primary patient samples. Notable’s high-throughput flow cytometry readout includes measures of apoptosis, proliferation, differentiation, and stemness. Additionally, Notable combines the data produced by its flow-cytometry platform with valuable patient clinical characteristics, allowing more complex analyses to be performed.
Notable’s ex vivo services combines machine learning, automation and highthroughput screening directly on patient samples to help predict responses to potential therapies, and ultimately determine which drugs or drug combinations will be most effective for specific types of cancers. The end to end integrated technology platform conducts functional drug sensitivity screening to predict drug efficacy, toxicity profiling, target validation, enhance patient selection, and predict patient response.
Currently, in addition to normal bone marrow and blood, Notable has leveraged its steady supply of patient samples, flexible automation and software platforms to build optimized drug sensitivity assays across a range of drug classes in primary patient samples from acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).
Notable has leveraged its steady supply of fresh patient samples, automation, and software to optimize drug sensitivity assays across a range of drug treatment classes. For example, chemotherapy, targeted agents (both small and large molecules), differentiation agents and immunotherapies have all been evaluated on the platform.
De-identified patient information collected in Notable’s clinical database may include demographic information, disease status (e.g. de novo vs. relapsed/refractory), clinical features, and/or clinical outcome. In Notable’s platform, correlation of patient responses with ex vivo drug sensitivity may guide future patient selection strategies and clinical trial designs.
Flow cytometry lends itself to multi-dimensional, complex analyses, with the ability to identify specific cell populations, including various populations of cancerous blasts and healthy cells, as well as cells undergoing apoptosis and differentiation-like changes. Differentiation is a mechanism of action of several recently approved drugs in AML that induce changes in blast cells into more mature phenotypes.
The Notable platform can be “tuned in” for each specific drug class or even for a specific drug. Each assay microenvironment is developed to accurately reflect a specific disease state. The microenvironmental conditions can be optimized for each specific drug class, as drug responses may be inadvertently influenced by different culture conditions. Additionally, the scalability and automation of the platform allows for rapid iteration of different conditions to identify optimal assay conditions
The Notable platform provides unique insight into inter and intra-patient heterogeneity and differential responses to therapies within single disease indications. By comparing experimental therapies to the current standard of care in primary patient samples, the Notable platform can provide valuable insights into potential efficacy compared to potential approved comparators. This is a powerful tool for drug development, both pre-clinically and clinically.